Search
Patexia Community

Innovation, Technology, and IP News

Feed tagged as "biotech":
BAXALTA INC. V. GENENTECH, INC. Before Moore, Plager, and Wallach.  Appeal from the District of Delaware Summary: A district court erred by interpreting... Read More »
BAXALTA INC. V. GENENTECH, INC. Before Moore, Plager, and Wallach.  Appeal from the District of Delaware Summary: A district court erred by interpreting... Read More »
ILLUMINA, INC. v. ARIOSA DIAGNOSTICS, INC. Before Lourie, Moore, and Reyna. Modified opinion following Ariosa rehearing petition. Summary: The Federal Circuit ... Read More »
In recent years, market interest in meat substitutes has aligned with advances in cell culture techniques to support the emergence of lab-grown meat or... Read More »
Until the cloning of Dolly the sheep in 1996 by scientists at the Roslin Institute, the idea of cloning a mammal, let alone a human being, was an idea relegated to... Read More »
On May 14, 2018, several important revisions to regulations of the Bayh-Dole Act (University and Small Business Patent Procedure Act of 1980, codified as 35 U.S.C... Read More »
In vitro gametogenesis (IVG) is a recent development in reproductive technology, and has been used for creating mouse embryos in vitro. IVG includes obtaining cells... Read More »
A new infertility technique, mitochondrial replacement therapy (MRT), has been used to create so called “three-parent” babies. MRT is used in cases when... Read More »
Lundbeck Pharmaceutical Company, headquartered in Denmark, recently announced the acquisition of Prexton Therapeutics B.V. for $1.1 billion (U.S.)(1).  Lundbeck... Read More »
On March 6, 2018, 23andMe, Inc. received the first-ever FDA authorization for a direct-to-consumer genetic test that analyzes gene mutations to help predict a... Read More »
On February 14, 2018, the U.S. Food and Drug Administration (FDA) approved Janssen Therapeutics’ Erleada (apalutamide), a non-steroidal antiandrogen for the... Read More »
In a recent development with the ongoing complex litigation involving Janssen Biotech’s arthritis biologic medicine Remicade (infliximab) and Celltrion’s... Read More »
In an effort to lay the groundwork for generic entry and reduced drug prices, the non-profit group Initiative for Medicines, Access and Knowledge, Inc. (I-MAK), with... Read More »
Written by Daniel A. Kamkar and Michael L. Fuller On October 9, 2017, California Governor Jerry Brown signed the new drug price transparency bill SB 17.[1]   ... Read More »
Written by Scott Siera, Ph.D. and Eric Furman, Ph.D. Seven years after Mylotarg® (gemtuzumab ozogamicin) was voluntarily withdrawn from the market, the U.S... Read More »
Written by Daniel A. Kamkar and Agnes Juang, Ph.D. On August 2, 2017, the U.S. Food and Drug Administration approved the use of Imbruvica® (ibrutinib) for the ... Read More »
Written by Marc Chatenay-Lapointe, Ph.D. and Jason Jardine On July 13, 2017, the U.S. Food and Drug Administration approved Tremfya (guselkumab), a biologic... Read More »
Written by Scott Siera, Ph.D. and Michael L. Fuller Stanford University v. The Chinese University of Hong Kong. Federal Circuit Appeal No. 2015-2011. Decided June ... Read More »
Written by Jeffrey C. Wu, Ph.D. and Brenden S. Gingrich, Ph.D. New York City took a step toward its goal of becoming a life sciences hub with a $5 million grant... Read More »
Written by Daniel A. Kamkar and Agnes Juang, Ph.D. Janssen Biotech Inc. and Celltrion Healthcare have taken the next step over Janssen’s blockbuster... Read More »
Show more Newsfeed posts
Menu